Allogene Therapeutics (ALLO) R&D/CAPEX US GAAP (year values)
2019 2020 2021 2022 2023   LTM ? CAGR 5 years ?
R&D/CAPEX, % 284.6% 292.6% 1 027% 4 939% 16 023%   43 227%  
Changes by years, y/y, % -4 411pp +8pp +734pp +3 912pp +11 084pp     +27.8%
Compare with other companies

Allogene Therapeutics. R&D/CAPEX, %

Allogene Therapeutics. R&D/CAPEX, changes, pp

Allogene Therapeutics (ALLO) R&D/CAPEX US GAAP (quarter values)
2023Q1 2023Q2 2023Q3 2023Q4 2024Q1   LTM ?
R&D/CAPEX, % 7 752% 21 541% 383 142% 30 199% 608 800%   43 227%
Changes by years, y/y, % +4 590pp +17 380pp +354 603pp +25 742pp +601 048pp    
Changes by quarters, q/q, % +3 295pp +13 789pp +361 601pp -352 942pp +578 601pp    

Allogene Therapeutics. R&D/CAPEX, %

Allogene Therapeutics. R&D/CAPEX, changes, pp

Allogene Therapeutics. R&D/CAPEX, changes, pp


Have an idea?
Blogs All blogs wire
Most useful
Most commented
NEWS
Trade Signals
Answers to questions
Books reviews
Corporate blogs
Forums All forums wire
Common
Stocks
Algotrading
Options
Cryptocurrencies
Forex
Brokers rating
Stocks Heat Map
Quotes
Fundamental analysis
Financials
Dividends
My portfolio
All companies
Stocks Calendar
Smartlab Smartlab Values
SiteMap
Ads
Contacts

Rules
Help
Feedback
Moscow Exchange is the source and the owner of marketdata. The users haven't right of further distribution or presentation of any data without written permission of Moscow Exchange, haven't right to create modified information for further public distribution to third parties.